Genocea Biosciences Inc (GNCAQ)

[NY1972]

EGFR–mutant is the most well known inhibigen?


Based upon retrospective clinical data suggesting that patients with TKI–naive, EGFR–mutant NSCLC may be more likely to respond to ICIs compared with patients with TKI–resistant disease, Lisberg et al conducted a phase II trial of pembrolizumab in patients who were TKI–naive with EGFR–mutant and PD-L1–positive (tumor proportion score ≥ 1%) metastatic NSCLC.11 The study was stopped early because of lack of efficacy among patients with confirmed EGFR mutations (ORR: 0%). Of note, two patients who went on to receive EGFR TKIs after pembrolizumab developed grade 3 transaminitis and grade 5 pneumonitis, respectively.

https://dailynews.ascopubs.org/do/10.1200/ADN.20.200428/full/